Evidence map›Paper›PMID 36748633›Full record

ArticleMicrobiology (Reading, England)2023

Adaptation of

Mona Bové, Mette Kolpen, Mads Lichtenberg, Thomas Bjarnsholt, Tom Coenye

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology (Reading, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Diversification ofMicroorganisms · 2025
    Article
  3. Article
  4. Microbial Musings: Winter 2023.Microbiology (Reading, England) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Mona BovéLaboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium.
Mette KolpenDepartment of Clinical Microbiology, Rigshospitalet, 2200 Copenhagen N, Denmark.
Mads LichtenbergCosterton Biofilm Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Thomas BjarnsholtCosterton Biofilm Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Tom CoenyeLaboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium.
University of Copenhagen · DKGhent University · BERigshospitalet · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present study we evaluated the fitness, antimicrobial susceptibility, metabolic activity, gene expression,

Indexed as

Pseudomonas aeruginosaTobramycinAnimalsAnti-Bacterial AgentsBacterial ProteinsBiofilmsChloramphenicolGene Expression Regulation, BacterialMiceQuorum SensingVirulence FactorsAnti-Bacterial AgentsBacterial ProteinsChloramphenicolTobramycinVirulence Factorsantimicrobial resistanceexperimental evolutionPseudomonas aeruginosa

Identifiers

PMID36748633
PMCPMC9993117
OpenAlexW4317390075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.